289 related articles for article (PubMed ID: 16603585)
1. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia.
Alfonso-Pérez M; López-Giral S; Quintana NE; Loscertales J; Martín-Jiménez P; Muñoz C
J Leukoc Biol; 2006 Jun; 79(6):1157-65. PubMed ID: 16603585
[TBL] [Abstract][Full Text] [Related]
2. PEG10 activation by co-stimulation of CXCR5 and CCR7 essentially contributes to resistance to apoptosis in CD19+CD34+ B cells from patients with B cell lineage acute and chronic lymphocytic leukemia.
Hu C; Xiong J; Zhang L; Huang B; Zhang Q; Li Q; Yang M; Wu Y; Wu Q; Shen Q; Gao Q; Zhang K; Sun Z; Liu J; Jin Y; Tan J
Cell Mol Immunol; 2004 Aug; 1(4):280-94. PubMed ID: 16225771
[TBL] [Abstract][Full Text] [Related]
3. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
4. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination.
López-Giral S; Quintana NE; Cabrerizo M; Alfonso-Pérez M; Sala-Valdés M; De Soria VG; Fernández-Rañada JM; Fernández-Ruiz E; Muñoz C
J Leukoc Biol; 2004 Aug; 76(2):462-71. PubMed ID: 15155773
[TBL] [Abstract][Full Text] [Related]
5. Regulation of human natural killer cell migration and proliferation by the exodus subfamily of CC chemokines.
Robertson MJ; Williams BT; Christopherson K; Brahmi Z; Hromas R
Cell Immunol; 2000 Jan; 199(1):8-14. PubMed ID: 10675270
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C; Dutertre CA; Le Garff-Tavernier M; Fournier N; Gaucher C; Glacet A; Jorieux S; Bihoreau N; Behrens CK; Béliard R; Vieillard V; Cazin B; Bourel D; Prost JF; Teillaud JL; Merle-Béral H
Br J Haematol; 2008 Mar; 140(6):635-43. PubMed ID: 18302712
[TBL] [Abstract][Full Text] [Related]
7. Neuroblastoma impairs chemokine-mediated dendritic cell migration in vitro.
Walker SR; Ogagan PD; DeAlmeida D; Aboka AM; Barksdale EM
J Pediatr Surg; 2006 Jan; 41(1):260-5. PubMed ID: 16410144
[TBL] [Abstract][Full Text] [Related]
8. CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells.
Iijima N; Yanagawa Y; Clingan JM; Onoé K
Int Immunol; 2005 Sep; 17(9):1201-12. PubMed ID: 16027136
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.
Lefebvre ML; Krause SW; Salcedo M; Nardin A
J Immunother; 2006; 29(4):388-97. PubMed ID: 16799334
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
[TBL] [Abstract][Full Text] [Related]
11. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
[TBL] [Abstract][Full Text] [Related]
12. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells.
Chunsong H; Yuling H; Li W; Jie X; Gang Z; Qiuping Z; Qingping G; Kejian Z; Li Q; Chang AE; Youxin J; Jinquan T
J Immunol; 2006 Nov; 177(10):6713-22. PubMed ID: 17082584
[TBL] [Abstract][Full Text] [Related]
13. CC chemokine ligand 25 enhances resistance to apoptosis in CD4+ T cells from patients with T-cell lineage acute and chronic lymphocytic leukemia by means of livin activation.
Qiuping Z; Jei X; Youxin J; Wei J; Chun L; Jin W; Qun W; Yan L; Chunsong H; Mingzhen Y; Qingping G; Kejian Z; Zhimin S; Qun L; Junyan L; Jinquan T
Cancer Res; 2004 Oct; 64(20):7579-87. PubMed ID: 15492285
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
Johnson AJ; Wagner AJ; Cheney CM; Smith LL; Lucas DM; Guster SK; Grever MR; Lin TS; Byrd JC
Br J Haematol; 2007 Dec; 139(5):837-44. PubMed ID: 17949452
[TBL] [Abstract][Full Text] [Related]
15. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking.
Ziegler E; Gueler F; Rong S; Mengel M; Witzke O; Kribben A; Haller H; Kunzendorf U; Krautwald S
J Am Soc Nephrol; 2006 Sep; 17(9):2521-32. PubMed ID: 16899521
[TBL] [Abstract][Full Text] [Related]
16. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.
Maddipatla S; Hernandez-Ilizaliturri FJ; Knight J; Czuczman MS
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4556-64. PubMed ID: 17671142
[TBL] [Abstract][Full Text] [Related]
18. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
19. Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration.
Humrich JY; Humrich JH; Averbeck M; Thumann P; Termeer C; Kämpgen E; Schuler G; Jenne L
Immunology; 2006 Feb; 117(2):238-47. PubMed ID: 16423060
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.
Le Garff-Tavernier M; Decocq J; de Romeuf C; Parizot C; Dutertre CA; Chapiro E; Davi F; Debré P; Prost JF; Teillaud JL; Merle-Beral H; Vieillard V
Leukemia; 2011 Jan; 25(1):101-9. PubMed ID: 20975664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
